Operol Dosage/Direction for Use

Propofol blood concentrations at steady state are generally proportional to infusion rates, especially in individual patients. Undesirable effects such as cardio respiratory depression are likely to occur at higher blood concentrations which result from bolus dosing or rapid increases in the infusion rate. An adequate interval (3 to 5 minutes) must be allowed between dose adjustments to allow for and assess the clinical effects.
When administering Propofol injectable emulsion by infusion syringe or volumetric pumps are recommended to provide controlled infusion rates.
Dosages and rates of administration in the following table 2 should be individualized and titrated to clinical response. Safety and dosing requirements to induction of anesthesia in pediatric patients have only been established for children 3 years of age or older. Safety and dosing requirements for the maintenance of anesthesia have only been established for children 2 months of age and older. (See Table 2.)

Click on icon to see table/diagram/image

Not recommended for use in children. Administration With Lidocaine: If lidocaine is to be administered to minimize pain an injection of Propofol, it is recommended that it be administered prior to Propofol administration or that it be added to Propofol immediately before administration and in quantities not exceeding 20 mg lidocaine/200 mg Propofol.
Dilution Prior to Administration: Propofol injectable emulsion is provided as ready-to-use formulation. However, should dilution be necessary, it should only be diluted with 5% Dextrose injection, USP, and it should not be diluted a concentration less than 2 mg/mL because it is an emulsion. In diluted form it has been shown to be more when in contact with glass than in plastic (95% potency after 2 hours of running infusion in plastic).
Compatibility of Propofol injectable emulsion with the co-administration of blood/serum/plasma has not been established. When administered using a y-type infusion set, Propofol injectable emulsion has been shown lobe compatible with the following intravenous fluids: 5% Dextrose Injection, Lactated Ringers Injection, Lactated Ringers and 5% Dextrose Injection, 5% Dextrose and 0.45% Sodium Chloride Injection, 5% Dextrose and 0.2% Sodium Chloride Injection.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Do not use if there is evidence of separation of the phases of the emulsion.